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Objective. To identify a genetic cause of early-onset systemic lupus erythematosus (SLE) in a large consanguineous family from Turkey and to study the mechanisms of the disease.
Methods. We performed whole-exome sequencing and single-nucleotide polymorphism array genotyping in family members with and without SLE. Protein and gene expression, cytokine profile, neutrophil extracellular trap (NET) formation, and presence of low-density granulocytes were evaluated in patient primary cells and serum samples.
Results. We identified a novel, homozygous, lossof-function mutation (p.Pro445Leufs*11) in the C1R gene. Using the Sanger method of DNA sequencing in 14 family members, we confirmed the presence of the mutation in 4 patients with SLE and in an asymptomatic 9-year-old girl. Complement levels were low in sera from patients with truncated C1r protein. Two siblings with SLE who were available for detailed evaluation exhibited strong type I interferon (IFN) inflammatory signatures despite their disease being clinically inactive at the time of sampling. The type I IFN transcriptional signature in the patients' blood correlated with disease expressivity, whereas the neutrophil signature in peripheral blood mononuclear cells was likely associated with disease severity. The female patient with SLE with the most severe phenotype presented with a stronger neutrophil signature, defined by enhanced NET formation and the presence of low-density granulocytes. Analysis of exome data for modifying alleles suggested enrichment of common SLE-associated variants in the more severely affected patients. Lupus-associated HLA alleles or HLA haplotypes were not shared among the 4 affected subjects.
Conclusion. Our findings revealed a novel highpenetrance mutation in C1R as the cause of monogenic SLE. Disease expressivity in this family appears to be influenced by additional common and rare genetic variants.
Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome characterized by significant organ involvement. Most patients are diagnosed during adulthood, and previous studies have demonstrated contributions of genetic, epigenetic, environmental, and hormonal factors in the pathogenesis of the disease. Genome-wide association studies have revealed .40 SLE susceptibility loci (1) . The disease-associated variants are generally common and have small but cumulative effects on susceptibility. Patients with early-onset symptoms, particularly during childhood, are more likely to have highly penetrant novel or rare variants in single genes (2) .
Reduced serum levels of complement have been linked to SLE pathogenesis. A systematic analysis of all reported cases showed that the strength of the association between complement deficiency and SLE depends on the position of the missing protein in the cascade, with the earlier complement components being associated with a higher incidence of SLE (C1 . C4 . C2) (3). Individuals with complete C1q deficiency have the highest risk of developing SLE, while deficiency of C1r/C1s has been associated with lower incidence (93% of patients with complete C1q deficiency develop SLE, versus 57% of C1r/C1s-deficient patients) (3). However, very few mutations in the complement genes have been reported. Biallelic loss-offunction mutations in C1S have been found in patients with lupus, but also in asymptomatic individuals (4) . Thus far, a loss-of-function mutation causing complete C1r deficiency has been reported in only a single individual: a male patient of African American ancestry who developed symptoms at the age of 3 years (5).
We studied a Turkish family in which multiple members had early-onset SLE. Because of the " family history of SLE and consanguinity, we hypothesized that affected patients in the family would carry a homozygous high-penetrance mutation in a single gene. We investigated the effects of C1r deficiency on innate and adaptive immune responses by analyzing whole blood cell transcriptional profiles, serum inflammatory cytokines, the presence of low-density granulocytes (a pathogenic subset described in SLE), and the formation of neutrophil extracellular traps (NETs). Finally, we analyzed the contribution of rare and common SLE-associated susceptibility alleles and HLA types to disease expressivity.
PATIENTS AND METHODS
Patients. All patients in this family were followed up at the Istanbul University Cerrahpasa School of Medicine. Patients 3 and 4 were also evaluated at the National Institutes of Health Clinical Center. All patients and their healthy family members who were enrolled in the study (or legal guardians in the case of those who were of minor age) provided written informed consent.
Whole-exome sequencing. Genomic DNA samples were isolated from peripheral blood. Whole-exome sequencing and data analysis were performed as previously described (6) . The Exome Aggregation Consortium, the 1000 Genomes Project, the dbSNP database, the National Heart, Lung, and Blood Institute Gene Ontology Exome Sequencing Project, the Clinseq database, and an in-house exome database were used to filter for rare candidate variants.
Sanger sequencing and single-base extension genotyping. We performed Sanger sequencing for C1R exons using a BigDye Terminator (version 1.1) Cycle Sequencing kit on a 3130xl Genetic Analyzer (both from Applied Biosystems). Sequencher software (Gene Codes) was used to analyze the sequencing data. We genotyped Turkish healthy controls and Behçet's disease patients for the presence of the p.Pro445Leufs*11 mutation, using the Sequenom iPlex Gold method. Genotypes were determined with Typer 4.0 software (Sequenom).
Targeted sequencing. Targeted sequencing of C1R was performed on pooled DNA samples from 300 patients with lateonset SLE. Nine amplicons covering the 9 exons of C1R were generated using high-fidelity polymerase AccuPrime Pfx SuperMix (Invitrogen). Pooled polymerase chain reaction (PCR) products were used to construct a library and were sequenced on a HiSeq instrument (Illumina).
HLA allele and haplotype analyses. Genomic DNA samples were analyzed using a HumanOmni5Exome Bead array and an iScan array reader (Illumina). Single-nucleotide polymorphism (SNP) genotypes were determined using GenomeStudio software (Illumina). SNPs residing within the major histocompatibility complex (MHC) locus (chromosome 6 [29-34 megabasepairs; hg19]) were extracted, and classic HLA alleles and haplotypes were determined by imputation using SNP2HLA software (http://software.broadinstitute.org/mpg/snp2hla/), with the Type 1 Diabetes Genetics Consortium data set as a reference.
Complement measurement. The levels of complement components C1r, C1s, C1q, C2, C3, and C4 were measured. A total complement activity enzyme immunoassay was performed at the National Jewish Health Advanced Diagnostic Laboratories (Denver, CO).
NanoString assay. We extracted RNA using a PAXgene Blood RNA system (Qiagen) and conducted gene expression analysis with the nCounter Analysis System (NanoString Technologies) using a code set designed to target 594 immunologically related genes. Total RNA (100 ng) was mixed with capture and reporter probes and hybridized on an nCounter Prep Station. For data analysis, nSolver software was used. The expression data were normalized to the geometric mean of results obtained with housekeeping genes.
Immunoblotting and cytokine measurement. Interferong (IFNg; 20 ng/ml) or tumor necrosis factor (20 ng/ml) was used to stimulate peripheral blood mononuclear cells (PBMCs) overnight. Whole-cell lysates from a patient and a healthy control were prepared using cell lysis buffer. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes. Immunoreactive proteins were detected with anti-C1r antibody Ab190800 (Abcam) and were visualized using ECL Plus Western blotting substrate (Thermo Fisher). Serum levels of cytokines were measured using a BioPlex Pro Human Cytokine 27-plex assay (Bio-Rad).
Cell isolation and quantification of NETs by immunofluorescence microscopy. For NET activity assays, normaldensity granulocytes were isolated from the red blood cell layer by dextran sedimentation. Donor normal-density granulocytes were plated at 100,000 cells per coverslip (coated with poly-Llysine; Sigma-Aldrich), incubated for 15 minutes, and then left untreated or treated for 3 hours with lipopolysaccharide (LPS) (100 ng/ml; Sigma-Aldrich). The coverslips were then fixed and stained for myeloperoxidase (MPO) and DNA analysis. Images were acquired on an LSM 510 META laser scanning confocal microscope (Carl Zeiss MicroImaging).
Flow cytometry. Donor PBMCs were blocked for 30 minutes in fluorescence-activated cell sorting solution (BioLegend). Anti-human surface markers were stained for 20 minutes using Pacific Blue-conjugated CD3 and CD19, allophycocyanin-conjugated CD10, fluorescein isothiocyanateconjugated CD14, and phycoerythrin-conjugated CD15 (all from BioLegend). Low-density granulocytes were identified as CD101, CD14 low , CD151. Real-time quantitative reverse transcription PCR (qRT-PCR). RNA was isolated using a Direct-zol RNA MiniPrep kit (Zymo Research). Total RNA (1 mg) was reverse transcribed with iScript reverse transcriptase (Bio-Rad), and qRT-PCR was performed using SsoAdvanced Universal SYBR Green (Bio-Rad). The primer sequences used are shown in Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40158/ abstract). Samples were run in duplicate using a CFX96 C1000 Touch Real Time Thermal Cycler (Bio-Rad), and data were analyzed with Bio-Rad CFX Manager software.
RESULTS
Clinical manifestations. The 4 affected family members ( Figure 1A ) shared a history of systemic inflammation, antinuclear antibody positivity, and malar rash suggestive of SLE. Each patient also presented with additional features of autoimmunity (see Supplementary Table 2 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40158/abstract).
The first affected sibling pair, patients 1 and 2 (both female), developed symptoms at the ages of 10 years and 2 years, respectively, and had a milder disease course than the second affected sibling pair, patients 3 (female) and 4 (male). At age 13 years, coinciding with puberty, patient 3 developed frequent severe headaches accompanied by long-lasting fevers (408C) and painful bilateral cervical lymphadenopathy. Her symptoms gradually increased to include malar rash, hemorrhagic vesicular eruptions, and proteinuria. Neurologic symptoms included delirium, hallucinations, and generalized tonic-clonic and absence seizures. Magnetic resonance imaging of the brain did not show evidence of focal lesions; however, lumbar puncture revealed increased intracranial pressure. Renal biopsy showed evidence of mesangial proliferative nephritis. Later in her disease course she developed diffuse hair loss, photosensitivity, and weight loss. She has residual neurologic and cognitive impairments, sicca syndrome, and aphthous ulcers. She is being treated with cyclophosphamide, azathioprine, hydroxychloroquine, and monthly intravenous methylprednisolone.
Her brother, patient 4, first developed symptoms, in the form of axillary lymphadenopathy and fevers (398C), at age 7 years. He was found to have proteinuria, and renal biopsy revealed acute proliferative glomerulonephritis. Immunofluorescence microscopy showed diffuse deposition of IgG, C3, and C1q. A year later, he developed a malar rash, photosensitivity, and a scaly erythematous patchy rash consistent with discoid lupus. He has also experienced photophobia, xerophthalmia, and aphthous ulcers. His symptoms have stabilized with immunosuppressive therapy (prednisone and azathioprine).
Genetic analysis. We performed whole-exome sequencing on the 4 patients with SLE, 4 unaffected parents, and 1 unaffected sibling ( Figure 1A) . We selected variants with a frequency of ,1% in various public databases and in our in-house database of 839 exomes ( Figure 1B) . Assumption of homozygous inheritance in affected patients allowed identification of 6 candidate variants, 5 of which were noncoding and thus were less likely to be pathogenic. Four rare or novel homozygous noncoding variants were inherited on the same haplotype, cosegregating with the novel coding variant in C1R (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40158/abstract).
All affected patients were homozygous for a 1-bp deletion (c.1332delT) in the C1R gene, corresponding to the p.Pro445Leufs*11 protein mutation ( Figure 1C ) (also see Supplementary Figure 1 , http://onlinelibrary.wiley. com/doi/10.1002/art.40158/abstract). The C1R gene encodes complement component 1, r subcomponent. Sanger sequencing of 14 family members confirmed the proper segregation of the p.Pro445Leufs*11 frameshift mutation and identified a 9-year-old asymptomatic girl in the family who carried the same homozygous mutation ( Figure 1A) . We genotyped 1,706 Turkish healthy controls and 1,618 Turkish patients with Behçet's disease and did not identify any carriers. Targeted sequencing in 300 patients with nonfamilial SLE with late-onset symptoms also did not identify any who had biallelic loss-of-function mutations in C1R. Western blotting of mutant PBMCs confirmed that the p.Pro445Leufs*11 variant creates truncated proteins (Figure 1D) . The truncated C1r protein lacks the light chain domain, which contains the catalytic domain of the activated (cleaved) C1r protein ( Figure 1C) ; therefore, the mutant protein is expected to be unable to cleave and activate C1s.
We attempted to explain the difference in disease severity in patients 1, 2, 3, and 4 by investigating for modifying alleles. We analyzed the exome data for rare exonic variants predicted to be damaging and for common SLEassociated variants, present in 1 or more patients. We found 3 rare coding variants in the CD44, DHCR7, and PXK genes, which have been implicated in the pathogenesis of SLE. Patients 1 and 2 had no variants, patient 3 carried 3 of these variants, and patient 4 carried 2 (Supplementary Table 4 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40158/abstract). We then investigated for the presence of common SLE-associated variants (SNPs) that were polymorphic in this family. We found 11 variants both in affected and in unaffected family members, as expected; however, they were enriched in patients 3 and 4 1834 DEMIRKAYA ET AL (the more severely affected patients) ( 1836 DEMIRKAYA ET AL 40158/abstract). In both of these patients, levels of C1r and C1s were notably low, while C1q, C2, C3, and C4 levels were normal to high. The total complement activity level was ,10 complement activity enzyme (CAE) units, which is far below the normal level of 55-145 CAE units. Samples from other affected subjects were not available for testing. Type I IFN signature and cytokine levels. We investigated for the presence of IFN gene expression signatures in whole blood samples from patients 3 and 4 and from the asymptomatic mutation-positive patient (AP5 in Figure 1 ). Both affected patients exhibited significant upregulation of IFN response genes, while the gene expression profile of the asymptomatic patient was similar to that of healthy controls (Figure 2A ) (also see Supplementary  Figure 2A , on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40158/ abstract). The male patient (patient 4) had a more pronounced type I IFN signature than the female patient (patient 3) (Supplementary Figure 2A) . The strong inflammatory signature in the male patient correlated with Figure 2 . Enhanced type I interferon (IFN) signature, inflammatory cytokine profile, high levels of NETosis, and low-density granulocyte signature in patients with the C1R mutation. A, NanoString analysis for type I IFN signature genes in symptomatic patients (P) with the mutation (patients 3 and 4), an asymptomatic patient with the mutation (AP5), and healthy controls (C). B, Cytokine profiling comparing sera from patients 3 and 4, the asymptomatic patient with the mutation, and healthy controls. Bars show the mean 6 SEM from analysis of 2 samples from each subject. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001; **** 5 P , 0.0001. NS 5 not significant; IL-2 5 interleukin-2; MCP-1 5 monocyte chemotactic protein 1; MIP-1a 5 macrophage inflammatory protein 1a. C, Spontaneous and lipopolysaccharide (LPS)-induced production of neutrophil extracellular traps by normal-density granulocytes from patients 3 and 4, analyzed by immunofluorescence. Myeloperoxidase appears in red and DNA in blue. Original magnification 3 20. D, Flow cytometric identification of low-density granulocytes (CD101, CD14 low , CD151) in peripheral blood mononuclear cells from patients 3 and 4 and a representative healthy control. Forward scatter is proportional to cell surface area or size, and side scatter is proportional to cell granularity or internal complexity. Values shown in red are the percentage of low-density granulocytes. significantly higher serum levels of proinflammatory and antiinflammatory cytokines and chemokines than in the female patient and the female asymptomatic mutationpositive subject ( Figure 2B ). Gene expression profiling of 594 immune-related genes demonstrated that patients 3 and 4 had increased expression of NF-kB and JAK/STAT pathway genes, while the profile in the asymptomatic mutation-positive family member appeared more similar to that in 4 healthy controls (Supplementary Figure 2B) .
Neutrophil phenotype. NETs have been shown to play an important role in modulating immune responses in a variety of inflammatory and autoimmune diseases, including SLE (7). We examined NET formation by normal-density granulocytes from patients 3 and 4 and from a control donor, by immunofluorescence. The female patient showed higher levels of spontaneous NETosis and LPS-induced NETosis compared to the male patient and the control donor ( Figure 2C ). The male patient exhibited some enhanced NET production when compared to the control, but the results were not as dramatic in the female patient.
A unique population of granulocytes known as lowdensity granulocytes has been associated with increased propensity for spontaneous NET formation (8) . The frequency of low-density granulocytes in PBMC fractions was quantified in patients 3 and 4 and a healthy control. The female patient showed a markedly higher percentage of low-density granulocytes (43.21%) compared to the male patient (5.34%) and the control donor (0.76%) ( Figure  2D ). Additionally, qRT-PCR analysis of the PBMCs for granulocyte-expressed proteins (MPO and cathepsin G) showed a higher granulocyte signature in PBMCs from patient 3 than from patient 4 (Supplementary Figure 2C) . These results suggest that the deficiency of C1r is associated with a proinflammatory granulocyte phenotype, including enhanced NETosis and an increased percentage of low-density granulocytes.
DISCUSSION
C1r is a serine protease that combines with C1q to form the C1 complex of the classical complement activation pathway. Loss-of-function mutations at the beginning steps of complement activation can have major effects on all downstream complement proteins. This is the second report of a novel high-penetrance mutation in C1R as the cause of monogenic and familial SLE. The C1r-deficient patients in the present study are phenotypically similar to the previously reported patient with this C1r deficiency (5) (see Supplementary This consanguineous family with multiple affected patients provided a platform for analysis of a role of modifying alleles in disease expressivity. Despite the common genetic and environmental background, we found phenotypic variations even among patients of the same sex, which cannot be fully explained by the novel deleterious mutation in C1R. Our data suggest that in addition to the C1R mutation, other rare and common gene variants may have contributed to disease severity (Supplementary Figure 3 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40158/abstract). In particular, patient 3, who had central nervous system and renal involvement, carried more SLE risk alleles than the other affected members of the family. Interestingly, classic SLE-associated HLA alleles were not identified in this family.
Until recently, dysregulated lymphocytes and aberrant antigen presentation have been considered major factors contributing to inflammation in SLE. In current models of lupus pathogenesis, activated granulocytes, enhanced NET formation, and type I interferon-producing cells have roles (9) . Enhanced NETosis in SLE patients may provide a potent stimulus for IFNa release by plasmacytoid dendritic cells and for inflammasome activation, and can also directly lead to tissue damage (10, 11) . One interesting finding of the present study was the difference in inflammatory signatures between the male and female patients, despite the fact that neither had active disease at the time of sampling. Patient 4 (the male patient) exhibited a higher inflammatory cytokine signature than patient 3 (the female patient). Patient 3 had the most severe disease and a stronger neutrophil signature, which might be related to the role of estrogen signaling in the regulation of immune pathways, or a sex-attributed difference in microbiota (12) .
Hypotheses on the mechanism of interaction between NETs and complement that have been reported in the literature are rather varied (13, 14) . The origin of low-density granulocytes remains unclear, and whether these cells are immature granulocytes or represent a distinct mature subset needs to be further elucidated (10) . It is possible that the immune dysregulation that follows C1r deficiency or the distinct cytokine milieu may have led to the generation of these cells. Hormonal or genetic factors may also play a role, given that the number of low-density granulocytes was significantly higher in the female patient. The specific role of sex in the regulation of adaptive and innate immune responses in SLE and its association with response to therapy need to be systematically studied in large cohorts of patients. Analyzing the combined effect of rare and common gene variants in SLE may shed light on interactions between signaling pathways and may further reveal potential therapeutic targets. 1838 DEMIRKAYA ET AL
